COGENT BIOSCIENCES, INC. (COGT)
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
📈 **POSITIVE** • High confidence analysis (87%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical